Aaron Goodman: ASH23 – I won’t be in attendance but my question would have been

Aaron Goodman shared a post on X/Twitter:

“ASH Plenary:

4 active drugs in myeloma makes more patients MRD negative then 3. Groundbreaking.

I won’t be in attendance but my question would have been “why not add teclistamab after IsaKRd” to make even more patients MRD negative.”

Source: Aaron Goodman/Twitter

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.